Consern Pharma Limited, a active public limited company, was established on 17 October 2001 in Ludhiana, Punjab, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24232PB2001PLC024715. Registered under ROC Roc Chandigarh. it is unlisted. It has an authorized capital of ₹3.50 M and a paid-up capital of ₹3.08 M.
Formerly known as Consern Pharma Private Limited. It upholds a compliant status. Employing 504 professional, Its leadership includes Seema Mahajan (Whole-Time Director), Kuljive Mahajan (Managing Director), Riaz K Mahajan (Additional Director). Past directors included Seema Mahajan, Mongi Lal, Ranjiv Kumar. It holds ₹8.00 Cr open charges and ₹16.69 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 308-C, Bhai Randhir Singh Nagar, Ludhiana, Punjab, 141012.
U24232PB2001PLC024715
024715
17 October 2001
₹3.50 M
₹3.08 M
Roc Chandigarh
Unlisted
Active
Explore comprehensive insights into Consern Pharma Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Seema Mahajan | Whole-Time Director | 17 Oct 2001 | Current |
| Kuljive Mahajan | Managing Director | 01 Apr 2004 | Current |
| Riaz K Mahajan | Additional Director | 01 Jun 2025 | Current |
| Atul Bhatara | Director | 01 Oct 2024 | Current |
| Suresh Goel | Additional Director | 01 Sep 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 31 Aug 2024 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2017 | Past |
| Pramod Abcsdd | Director | 07 Mar 2012 | Past |
| Pramod Abcsdd | Director | 07 Mar 2012 | Past |
| Pramod Abcsdd | Director | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Consern Pharma Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 46.39% increase. The company also saw a substantial improvement in profitability, with a 76.2% increase in profit. The company's net worth Soared by an impressive increase of 60.68%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Consern Pharma had a promoter holding of 94.99% and a public holding of 5.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹80,000,000.00
₹166,910,653.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Jan 2025 | Others | ₹8.00 Cr | Open |
| 26 Feb 2020 | Indian Overseas Bank | ₹7.96 Cr | Satisfied |
| 22 Apr 2019 | Others | ₹5.00 M | Satisfied |
| 07 Oct 2017 | Hdfc Bank Limited | ₹6.70 Cr | Satisfied |
| 03 Jul 2010 | Indian Overseas Bank | ₹4.00 M | Satisfied |
Explore comprehensive loan charge details -
Consern Pharma has a workforce of 504 employees as of Sep 25, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Consern Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Consern Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Suresh Goel was appointed as a Additional Director was appointed as a Additional Director on 01 Sep 2025 & has been associated with this company since 3 months . was documented.
Progress on Riaz K Mahajan was appointed as a Additional Director was appointed as a Additional Director on 01 Jun 2025 & has been associated with this company since 6 months 1 day . was documented.
A charge with Others amounted to Rs. 80.00 M with Charge ID 101033908 was registered on 15 Jan 2025. was recorded as a recent event.
The activity A charge registered on 26 Feb 2020 via Charge ID 100333938 with Indian Overseas Bank was fully satisfied on 16 Dec 2024. was completed.
Progress on Atul Bhatara was appointed as a Director was appointed as a Director on 01 Oct 2024 & has been associated with this company since 1 year 2 months . was documented.
Progress on Consern Pharma Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
The CIN of Consern Pharma Limited is U24232PB2001PLC024715.
Consern Pharma Limited is headquartered at 308-C, Bhai Randhir Singh Nagar, Ludhiana, Punjab, 141012.
Consern Pharma Limited was incorporated on 17 October 2001.
The current directors of Consern Pharma Limited are
The primary industry of Consern Pharma Limited is Manufacturing.
Consern Pharma Limited is unlisted.
The authorized capital of Consern Pharma Limited is ₹3.50 M, and the paid-up capital is ₹3.08 M.
The compliance status of Consern Pharma Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX